L Ma1, M Liu, F-L Li. 1. Department of Cardiology, Shanxian Central Hospital, Heze, P.R.China. lifenglinghao@126.com.
Abstract
OBJECTIVE: To investigate the therapeutic effects of ticagrelor and clopidogrel on patients with acute myocardial infarction (AMI) and its effect of lncRNA BANCR. PATIENTS AND METHODS: A total of 169 AMI patients admitted to our hospital from June 2015 to July 2018 were prospectively selected, of which 82 patients treated with clopidogrel were enrolled in the clopidogrel group (CG) and 87 patients treated with ticagrelor were enrolled in the ticagrelor group (TG). The therapeutic effect, serum lncRNA BANCR, platelet count, maximum platelet aggregation rate, serum troponin Ⅰ (cTnI), serum creatine kinase isoenzyme (CK-MB), and serum high sensitivity C-reactive protein (hs-CRP) levels of the two groups of patients were detected and compared before and after treatment. The incidence of adverse reactions (ADR) and the occurrence of major adverse cardiovascular events (MACE) within 6 months after treatment were recorded and compared, and the predictive value of BANCR on therapeutic effect and MACE occurrence was analyzed. RESULTS: The therapeutic effect of TG was remarkably better than that of CG (p<0.05), and the improvement of serum BANCR, platelet count, maximum platelet aggregation rate, cTnⅠ, CK-MB, hs-CRP levels of the TG were remarkably better than that of CG (p<0.05). The incidence of ADR and MACE in the TG were notably lower than the CG (p<0.05). The expression of BANCR in the serum of patients with better therapeutic effect was significantly lower than that of patients with invalid treatment (p<0.05). The expression of BANCR in the serum of patients without MACE was significantly lower than that of patients with MACE (p<0.05). BANCR had high predictive value for both therapeutic effect and occurrence of MACE. CONCLUSIONS: The effect of ticagrelor on AMI patients is significantly better than clopidogrel, and has higher safety. It can effectively reduce the content of BANCR in the serum of AMI patients, which is worthy of further promotion in clinical practice. Moreover, the predictive value of BANCR for the efficacy of AMI patients and the occurrence of MACE was high.
OBJECTIVE: To investigate the therapeutic effects of ticagrelor and clopidogrel on patients with acute myocardial infarction (AMI) and its effect of lncRNA BANCR. PATIENTS AND METHODS: A total of 169 AMI patients admitted to our hospital from June 2015 to July 2018 were prospectively selected, of which 82 patients treated with clopidogrel were enrolled in the clopidogrel group (CG) and 87 patients treated with ticagrelor were enrolled in the ticagrelor group (TG). The therapeutic effect, serum lncRNA BANCR, platelet count, maximum platelet aggregation rate, serum troponin Ⅰ (cTnI), serum creatine kinase isoenzyme (CK-MB), and serum high sensitivity C-reactive protein (hs-CRP) levels of the two groups of patients were detected and compared before and after treatment. The incidence of adverse reactions (ADR) and the occurrence of major adverse cardiovascular events (MACE) within 6 months after treatment were recorded and compared, and the predictive value of BANCR on therapeutic effect and MACE occurrence was analyzed. RESULTS: The therapeutic effect of TG was remarkably better than that of CG (p<0.05), and the improvement of serum BANCR, platelet count, maximum platelet aggregation rate, cTnⅠ, CK-MB, hs-CRP levels of the TG were remarkably better than that of CG (p<0.05). The incidence of ADR and MACE in the TG were notably lower than the CG (p<0.05). The expression of BANCR in the serum of patients with better therapeutic effect was significantly lower than that of patients with invalid treatment (p<0.05). The expression of BANCR in the serum of patients without MACE was significantly lower than that of patients with MACE (p<0.05). BANCR had high predictive value for both therapeutic effect and occurrence of MACE. CONCLUSIONS: The effect of ticagrelor on AMI patients is significantly better than clopidogrel, and has higher safety. It can effectively reduce the content of BANCR in the serum of AMI patients, which is worthy of further promotion in clinical practice. Moreover, the predictive value of BANCR for the efficacy of AMI patients and the occurrence of MACE was high.